Work

Pharmacokinetic (PK) assessment of revumenib in patients with relapsed/refractory (R/R) acute leukemias harboring a KMT2A rearrangement ( KMT2A r) or NPM1 mutation ( NPM1 m): Impact of food and concomitant medications.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.6528

Authors: Enoch Cobbina, Joshua Stewart, YuWei Lin, Angela R. Smith, Ophelia Yin, Ghayas C. Issa

Institutions: Syndax Pharmaceuticals (United States), Certara (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162528281

Cites:

Cited by: 1

Related to: